BioMarin Pharmaceutical reported $0.23 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 0.23 1.49 0.12 Nov/02
FY2026Q2 Jun/2026 1.20 0.95 1.44 Aug/06
FY2026Q1 Mar/2026 0.76 0.74 1.13 May/04
FY2025Q4 Dec/2025 0.46 0.77 0.92 Feb/23
FY2025Q3 Sep/2025 0.12 0.86 0.91 Oct/27




Eps Change Date
Acadia Pharmaceuticals USD 0.31 0.13 Sep/2026
Agios Pharmaceuticals USD -1.09 0.6 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
Amgen USD 6.45 0.16 Sep/2026
Bayer EUR 0.31 0.64 Sep/2026
Biogen USD 2.62 0.98 Sep/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Gilead Sciences USD 2.55 9.3 Sep/2026
Incyte USD -3.6 6.69 Sep/2026
Insmed USD -0.46 0.4 Sep/2026
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
Moderna USD 0.38 2.35 Sep/2026
Neurocrine Biosciences USD 3.29 0.44 Sep/2026
PTC Therapeutics USD -0.62 1.54 Sep/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Roche Holding CHF 10.98 2.61 Jun/2026
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Sanofi EUR 0.14 2.02 Jun/2026
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
Ultragenyx Pharmaceutical USD -1.16 0.26 Sep/2026
United Therapeutics USD 5.71 1.56 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026